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BACKGROUND: Cancer outcomes are poor in socioeconomically deprived communities, with low symptom awareness contributing
to prolonged help-seeking and advanced disease. Targeted cancer awareness interventions require evaluation.
METHODS: This is a randomised controlled trial involving adults aged 40+ years recruited in community and healthcare settings in
deprived areas of South Yorkshire and South-East Wales. Intervention: personalised behavioural advice facilitated by a trained lay
advisor. Control: usual care. Follow-up at two weeks and six months post-randomisation. Primary outcome: total cancer symptom
recognition score two weeks post-randomisation.
RESULTS: Two hundred and thirty-four participants were randomised. The difference in total symptom recognition at two weeks
[adjusted mean difference (AMD) 0.6, 95% CI: −0.03, 1.17, p= 0.06] was not statistically significant. Intervention participants
reported increased symptom recognition (AMD 0.8, 95% CI: 0.18, 1.37, p= 0.01) and earlier intended presentation (AMD −2.0, 95%
CI: −3.02, −0.91, p < 0.001) at six months. “Lesser known” symptom recognition was higher in the intervention arm (2 weeks AMD
0.5, 95% CI: 0.03, 0.97 and six months AMD 0.7, 95% CI: 0.16, 1.17). Implementation cost per participant was £91.34, with no
significant between-group differences in healthcare resource use post-intervention.
CONCLUSIONS: Improved symptom recognition and earlier anticipated presentation occurred at longer-term follow-up. The
ABACus Health Check is a viable low-cost intervention to increase cancer awareness in socioeconomically deprived communities.
CLINICAL TRIAL REGISTRATION: ISRCTN16872545.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01524-5
BACKGROUND
Inequalities in cancer survival exist in the United Kingdom [1, 2].
The deprivation gap in cancer outcomes partly reflects socio-
economic differences in stage at diagnosis [3], with prolonged
time to symptom presentation contributing to later stage
diagnosis in lower socioeconomic groups [4, 5]. Cancer risk
behaviours including smoking, alcohol and poor diet also con-
tribute to higher cancer incidence and mortality in deprived
communities [6]. Since the inception of the UK National
Awareness and Early Diagnosis Initiative [7] and International
Cancer Benchmarking Partnership [8], efforts have been focussed
on understanding the root causes of international variation in
cancer outcomes, including later symptom presentation and later
stage diagnosis.
Early symptoms of common cancers can be difficult to
recognise, and low awareness of potential cancer symptoms has
been linked to longer time to help-seeking [9, 10]. Previous studies
have highlighted key behavioural influences on cancer symptom
presentation, including perceived practical and emotional barriers
[11], worry about wasting the doctor’s time [12] and fearful and
fatalistic beliefs about cancer [13, 14], especially among adults
living in deprived communities [15–17]. While evidence suggests
that interventions delivered via mass media campaigns can
improve cancer outcomes [18–20], they may not reach people
from lower socioeconomic groups [21].
Innovative approaches are therefore needed to expedite cancer
diagnosis and improve outcomes among people from lower
socioeconomic groups who are disproportionately affected by
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cancer. Cancer awareness interventions that are targeted at social
and community networks have the potential to engage people
living in deprived areas by signalling that timely help-seeking for
suspected cancer symptoms is welcomed and legitimised [22].
Building on personal connections and trust using the trained peer
supporter model may be a powerful way of spreading positive
cancer awareness messages through the community. This is an
established idea, especially in areas of deprivation where long-
term health may not be a priority due to low resources [23].
Evidence suggests that community-based behavioural interven-
tions facilitated by trained and trusted peer supporters are
important for engaging underserved populations in cancer
awareness and normalising earlier help-seeking [24, 25].
We developed the Awareness and Beliefs About Cancer
(ABACus) Health Check, a targeted and tailored intervention
designed to raise awareness of common cancers and encourage
timely symptom help-seeking among adults living in socio-
economically deprived communities [26]. Early evidence demon-
strated successful engagement and potential for intervention
scalability, reach and adoption in non-medical community settings
in areas of deprivation [27]. We trialled the effectiveness of the
intervention in increasing cancer awareness and help-seeking
behaviour among adults recruited in socioeconomically deprived
areas of Yorkshire and Wales.
METHODS
Trial methods are reported in detail in the published protocol [28].
Study design
This was an unblinded, individually randomised controlled trial of a
facilitated Health Check intervention hosted online and delivered by three
trained lay advisors in areas of high deprivation in South and West
Yorkshire and South-East Wales.
Participants
Participant inclusion criteria were: adults aged ≥40 years recruited
from venues in socioeconomically deprived areas (i.e. lowest quintile
measured using the Index of Multiple Deprivation (IMD) [29]/Welsh Index
of Multiple Deprivation (WIMD) [30]) of South and West Yorkshire
(Sheffield, Barnsley, Rotherham, Wakefield, Doncaster) or South-East Wales
(Merthyr Tydfil and Newport). Exclusion criteria were: non-English speak-
ing, unable to give written informed consent, or participation in the Phase
2 study [28].
Recruitment and settings
Full details of recruitment and settings for recruitment are published [27].
Briefly, local delivery organisations situated in eligible community and
healthcare settings (i.e. located in an area of socioeconomic deprivation)
were approached by the lay advisors, who sought permission to access the
organisation’s facilities for recruitment purposes and delivering the Health
Check intervention. They acted as recruitment venues and enabled access
to members of the public and provided a suitable private space for the
intervention delivery. Community settings included venues hosting local
community events and groups, for example, job shops, libraries and
sheltered housing. Healthcare settings included general practitioner (GP)
surgeries and pharmacies.
Sample size
We aimed to recruit 246 participants providing 90% power to detect an
effect size of 0.5 in the primary outcome (using a two-sided t test, at the
5% significance level and assuming 30% attrition) to demonstrate an
average increased recognition of one cancer symptom (SD= 2.2).
Randomisation
Immediately following baseline data collection, participants were rando-
mised to the intervention or control. Participants were randomised using
permuted blocks of size 2, 4 and 6 on a 1:1 ratio and informed immediately
of the outcome by the lay advisor.
Intervention
The ABACus Health Check intervention was specifically developed to
improve awareness of a range of cancers and reduce time to symptom
presentation among adults living in areas of socioeconomic deprivation in
the UK [22, 26]. The intervention was co-produced with local stakeholders
and grounded in behaviour change theory, with social support and
enablement provided by a credible lay advisor identified as key
intervention functions [26]. In keeping with the principles of co-production,
the intervention focussed on cancer symptom awareness, while acknowl-
edging stakeholders’ views on the importance of addressing underlying
cancer risk factors. It comprises an interactive touchscreen questionnaire
about common cancer symptoms, cancer screening and risk factors
(smoking, alcohol, diet and activity) with personalised results, support and
advice delivered by a trained lay advisor drawing on seven behaviour
change techniques (i.e. Information about health consequences; Prompts/
cues; Credible source; Restructuring the social environment; Social support;
Goal setting (behaviour) and Action planning) tailored to the individual’s
results [22]. Three lay advisors were specifically employed to recruit
participants and deliver the Health Check. They all had either under-
graduate or Master’s level education and had a health promotion
background. Further description of the intervention reported according
to the TIDieR checklist [31] can be found in Supplementary Table 1.
Control
Participants randomised to the control group were provided with the usual
available care and support accessible through their GP or community
organisations where applicable.
Data collection
Data were collected at baseline, two weeks and six months following
randomisation. At baseline, data were collected face-to-face using an iPad
and entered directly into a bespoke study database. Subsequent data
collection was carried out over the telephone or by postal survey
according to the participant’s preference. Participants were offered a total
of £15 in high street shopping vouchers as an incentive to take part, one
supplied at baseline (£10) and one after completion of the six months
follow-up questionnaire (£5).
Process evaluation
The method and results of the process evaluation are reported separately
(HQ-S, YM, SG, SS, VS, JH, et al. unpublished) and included participant
interviews at two to six weeks post-baseline, audio recordings and
observations of the Health Check delivery, interviews with the lay advisors
prior to and post participant recruitment and recruitment day logs written
by the lay advisors.
Primary outcome
The primary outcome was total cancer symptom recognition score
measured two weeks after randomisation, using an adapted version of
the Awareness and Beliefs about Cancer measure (ABC) [32]. See
Supplementary Table 2 for further details on measures used.
Secondary outcomes
Secondary outcomes included anticipated symptom presentation for
selected symptoms (unusual lump, rectal bleeding, persistent cough,
unexplained weight loss); barriers to symptom presentation; beliefs about
cancer; state anxiety (details of these in Supplementary Table 2); Health
Check implementation costs; cost of subsequent healthcare resource use;
demographic and health-related variables.
Health Check intervention implementation costs. Intervention costs con-
sidered in the health economic analysis included the cost of training the
lay advisors, costs related to intervention face-to-face delivery and
equipment to deliver the Health Check, which was assumed to be
replaced after a mean lifespan of 3 years. Resource use and costs
associated with intervention implementation were taken from recruitment
day logs and notes, receipts and through discussions with the study team.
Training costs were calculated based on data obtained from study training
logs, costed using published unit costs [33]. ABACus Health Check
development costs were not included in these costs as the intervention
was fully developed [26] at the time of the study.
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Cost of subsequent healthcare resource use. Subsequent healthcare
resource use associated with symptoms that could be due to cancer at
baseline and six months including primary care consultations, accident and
emergency department visits, outpatient appointments, inpatient stays,
imaging and investigations and advice related to potential cancer
symptoms was established using a Client Service Receipt Inventory (CSRI)
[34], adapted for healthcare resource use collection in people living in
socioeconomically deprived. Each CSRI questionnaire asked for potential
cancer symptom-related healthcare resource use in the past six months.
Costs were assigned as 2018 Pound Sterling using published unit costs
[33, 35]. Cancer treatment related to confirmed cancer was collected but
not included in the total cost.
Demographic and health-related variables. Demographic background
variables included age, gender, ethnicity, current relationship status,
highest level of education, employment and home ownership. IMD [29]
and WIMD [30] scores were calculated from postcodes. Experience of
cancer (self, family and friends) and self-rated health were assessed.
Statistical analyses
Data were analysed using intention-to-treat principles (i.e. participants
remained in the groups to which they were assigned irrespective of
intervention received) using complete cases. The primary analyses applied
a linear model to total cancer symptom recognition score at two weeks
follow-up. Mixed-effects two-level partial cluster regression models were
used to adjust for lay advisors as a stratification variable and to allow for
clustering by advisor. The distributional assumptions of the linear model
were checked and transformed where appropriate. Bootstrapping was
used to generate regression coefficients and confidence intervals (CIs) if
the distributions remained non-normal. The mean (SD) score for the
intervention and control groups at baseline and follow-up were tabulated.
The primary outcome effect was presented adjusted for baseline score,
with 95% CI. Pre-specified exploratory subgroup analyses were run for age,
gender, recruitment setting and education. Secondary outcomes were
analysed similarly. The consistency of conclusions drawn from the primary
analysis was investigated by conducting sensitivity analyses for: (i) missing
responses (i.e. not missing completely at random); (ii) data collected
outside the designated two weeks follow-up window. Psychometric testing
of baseline data was conducted to assess the internal validity and reliability
of the adapted ABC measures, with Cronbach’s alpha coefficient to assess
the internal consistency of the scales and appropriate regressions applied
to subscales generated from factor analysis (Supplementary Table 3).
For all analyses, two-sided 95% CIs and p values were calculated. p
Values < 0.05 were considered statistically significant. Statistical analyses
were conducted using IBM SPSS version 25 and STATA version 15.
Health economic analyses
The cost differences between intervention and control groups in the six
months post-randomisation, based on all available cases, were calculated
using SPSS version 26. Independent samples t tests, adjusted using
Bonferroni–Holm sequential corrections [36], were used for comparison of
control and intervention group data and paired t tests for within-group
differences between baseline and six months follow-up, with a 5%
significance level. A within-trial cost-effectiveness analysis calculated the
incremental cost per point improvement in cancer symptom awareness
score at the six months follow-up point in the intention-to-treat
population. Trial results extrapolated to a longer time horizon and
published evidence were used to estimate the incremental cost per
quality-adjusted life-year (QALY) gained based on a combined decision
tree and Markov model constructed using Microsoft Excel and Visual Basics
for Applications over a five year time horizon. This analysis assumed that
encouraging earlier presentation with cancer symptoms would result in
potential effects on health outcomes and healthcare costs based on a
simulated cohort of 100,000 people living in socioeconomically deprived
areas of the UK. The analysis was undertaken from an NHS and personal
social services perspective with costs and outcomes discounted at an
annual rate of 3.5%. Deterministic and probabilistic sensitivity analyses
were undertaken to test the robustness of the results.
RESULTS
Overall, 448 members of the public were approached to take part
during the study period between December 2017 and January
2019, of whom 29 were ineligible, 42 declined due to lack of
interest and 141 declined for other reasons (e.g. insufficient time)
(Supplementary Table 4). Following consent, two participants
were withdrawn due to incomplete baseline questionnaires. A
total of 234 participants (82 from South East Wales (35%) and 152
from South and West Yorkshire (65%)) were randomised to the
intervention (n= 117, 50%) or control (n= 117, 50%) (Fig. 1).
Despite a lower than planned sample recruited (n= 249), the
study attrition rate of 9.5% [27] was much lower than anticipated
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Did not meet criteria, n = 29
Declined, n = 42
Other, n = 141
Fig. 1 Consort flow diagram.
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n % n % n %
Age (years), mean (SD) 61.9 (11.47) 60.7 (11.85) 61.3 (11.65)
Gender
Male 50 42.7 36 30.8 86 36.8
Female 67 57.3 81 69.2 148 63.2
Highest level of education
No qualifications/left school at 16 years 25 21.4 19 16.2 44 18.8
Finished school at or before age of 15 years 36 30.8 39 33.3 75 32.1
Completed GCSEs, O-Levels or equivalent 21 17.9 26 22.2 47 20.1
Completed A levels or equivalent 5 4.3 9 7.7 14 6.0
Completed further education but not degree 22 18.8 14 12.0 36 15.4
Completed a bachelor’s degree/masters/PhD 8 6.8 10 8.5 18 7.7
Employment status
Employed full time 15 12.8 11 9.4 26 11.1
Employed part time 12 10.3 9 7.7 21 9.0
Full-time homemaker 1 0.9 2 1.7 3 1.3
Retired 58 49.6 50 42.7 108 46.2
Unemployed 15 12.8 22 18.8 37 15.8
Self-employed 3 2.6 3 2.6 6 2.6
Disabled or too ill to work 13 11.1 19 16.2 32 13.7
Prefer not to say 0 0.0 1 0.9 1 0.4
Home/living arrangement
Own outright 48 41.0 34 29.1 82 35.0
Own mortgage 8 6.8 12 10.3 20 8.5
Rent form local authority/housing association 44 37.6 49 41.9 93 39.7
Rent privately 14 12.0 17 14.5 31 13.2
Living with family or friends 3 2.6 3 2.6 6 2.6
Prefer not to say 0 0.0 2 1.7 2 0.9
Current relationship
Living with partner/spouse 63 53.8 60 51.3 123 52.6
Living alone (not living with partner/spouse) 51 43.6 52 44.4 103 44.0
Prefer not to say 3 2.6 5 4.3 8 3.4
Ethnic group
White 115 98.3 114 97.4 229 97.9
White and Black Caribbean 0 0.0 1 0.9 1 0.4
White and Black African 1 0.9 0 0.0 1 0.4
Pakistani 1 0.9 0 0.0 1 0.4
Caribbean 0 0.0 1 0.9 1 0.4
Other ethnic group 0 0.0 1 0.9 1 0.4
Welsh Index of Multiple Deprivation (n= 82)
10% most deprived 15 36.6 16 39.0 31 37.8
10–20% most deprived 9 22.0 9 22.0 18 22.0
20–30% most deprived 7 17.1 6 14.6 13 15.9
30–40% most deprived 6 14.6 3 7.3 9 11.0
50% least deprived 4 9.8 7 17.1 11 13.4
Index of Multiple Deprivation (n= 152)
10% most deprived 47 61.8 37 48.7 84 55.3
20% most deprived 9 11.8 12 15.8 21 13.8
30% most deprived 3 3.9 8 10.5 11 7.2
40% most deprived 4 5.3 8 10.5 12 7.9
50% most deprived 2 2.6 0 0.0 2 1.3
50% least deprived 3 3.9 6 7.9 9 5.9
40% least deprived 1 1.3 2 2.6 3 2.0
30% least deprived 6 7.9 1 1.3 7 4.6
20% least deprived 1 1.3 1 1.3 2 1.3
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Recruited participants had a mean age of 61.3 years
(SD= 11.65). Most participants were white (229/234, 97.9%) and
around two thirds were female (148/234, 63.2%). Around half of
participants were retired (108/234, 46.2%) and had no formal
qualifications or finished school at age ≤16 years (129/234, 55.1%).
Around half of participants were living with a partner or spouse
(123/234, 52.6%) and just over one-third were renting from a local
authority or housing association (93/234, 39.7%). Most participants
were resident in the 20% most deprived areas (WIMD: 49/82,
59.8%; IMD: 105/152, 69.1%). Baseline characteristics for partici-
pants (experiences of cancer) were well balanced between trial
groups (Table 1). Baseline data were comparable between groups
with a mean baseline cancer symptom recognition score of 9.0/12
and 8.9/12 in the control and Health Check groups, respectively
(Supplementary Table 5). Retention was high at two weeks (212/
234, 90.5%) and six months follow-up (99/234, 85.0%) and
comparable between groups. No further sensitivity analyses were
required (Supplementary Tables 6 and 7).
Primary outcome
Difference in cancer symptom recognition score at two weeks
follow-up was not statistically significant between groups
(adjusted mean difference (AMD): 0.6, 95% CI: −0.03 to 1.17, p
= 0.06) (Table 2). There was no evidence of an intervention effect
in the pre-specified subgroup analyses and one ad hoc subgroup
analysis (Supplementary Table 8). Primary outcome data collected
outside the two weeks follow-up window were adjusted to include
data collected outwith the two week window, with no change in
difference (Supplementary Table 9).
Secondary outcomes
At six months follow-up, participants allocated to the Health
Check had statistically significantly increased symptom recogni-
tion (AMD: 0.8, 95% CI: 0.18 to 1.37, p= 0.01) and reported shorter
anticipated time to presentation (AMD: −2.0, 95% CI: −3.02 to
−0.91, p < 0.001) compared to control. There were no statistically
significant differences between groups at two weeks in antici-
pated symptom presentation (AMD: −0.8, 95% CI: −1.79 to 0.29),
perceived barriers to presentation (AMD: 0.1, 95% CI: −0.23 to
0.41), beliefs about cancer (AMD: −0.02, 95% CI: −0.50 to 0.45)
and state anxiety (AMD: 0.03, 95% CI: −0.11 to 0.18). There was no
evidence of difference between groups in perceived barriers
(AMD: 0.3, 95% CI: −0.36 to 0.91), beliefs about cancer (AMD:
−0.03, 95% CI: −0.45 to 0.38) and state anxiety (AMD: 0.81, 95% CI:
−0.10 to 1.72) at six months (Table 2).
A large ceiling effect was observed for recognition of “well-
known” cancer symptoms at baseline (Fig. 2). Health Check
intervention participants had higher recognition of “lesser known”
cancer symptoms at two weeks (AMD: 0.5, 95% CI: 0.03 to 0.97)
and six months (AMD: 0.1, 95% CI: 0.16 to 1.17). No between-
group difference was found for recognition of “well-known”
cancer symptoms at two weeks (AMD: 0.1, 95% CI: −0.16 to 0.27)
and six months (AMD: 0.1, 95% CI: −0.09 to 0.28) (Table 3).
Health economics
During the study, 116 Health Checks were undertaken by three lay
advisors at an intervention implementation cost of £91.34 per
participant. This consisted of £12.51 lay advisor training cost,
£21.05 staff cost for Health Check delivery and £57.78 equipment
cost (including online hosting and technical support of the Health
Check questionnaire, iPads, laptops and mobile phones and
mobile printing equipment) per participant. Total healthcare costs
related to symptoms that could be due to cancer (based on
available cases) in the six months follow-up period included the
cost of all primary and secondary care as well as diagnostic
investigations and symptom-related advice (Table 4). Participants
in the Health Check intervention group had £11.64 (95% CI: −
£198.77 to £175.50) lower total healthcare costs compared to the
control group in the six months after baseline. The difference was
not statistically significant (p= 0.90). After adding the Health
Check implementation costs for all participants in the Health
Check intervention group who had available healthcare resource
use data, participants in the intervention group accrued a mean
cost of £225.82 (SD= £641.41) at six months. The difference of
£79.70 (95% CI: −£107.43 to £266.84) compared to the control








n % n % n %
10% least deprived 0 0.0 1 1.3 1 0.7
Have you had cancer?
Yes 27 23.1 21 18.3 48 20.7
No 90 76.9 94 81.7 184 79.3
Has your partner had cancer?
Yes 21 18.1 15 12.9 36 15.5
No 95 81.9 101 87.1 196 84.5
Has a close family member had cancer?
Yes 83 70.9 93 79.5 176 75.2
No 34 29.1 24 20.5 58 24.8
Has another family member had cancer?
Yes 65 55.6 61 53.0 126 54.3
No 52 44.4 54 47.0 106 45.7
Has a close friend had cancer?
Yes 67 57.8 65 56.5 132 57.1
No 49 42.2 50 43.5 99 42.9
Has another friend had cancer?
Yes 80 69.0 72 62.6 152 65.8
No 36 31.0 43 37.4 79 34.2
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Based on the differences in costs and outcomes in the
intention-to-treat population, the Incremental Cost-Effectiveness
Ratio (ICER) was calculated to be £108.85 per point improvement
in cancer symptom recognition score, with ICERs ranging from
£31.51 to £205.97 in the sensitivity analysis. When the incremental
cost of Health Check implementation, changes in healthcare
resource use and downstream changes in healthcare cost as well
as survival due to potentially earlier cancer detection are
considered, the model-based cost-utility analysis estimated that
the intervention is on average £4.08 less costly and produces
0.005 more QALYs than the control and thus is dominating. No
change to the base case conclusion was found in the one-way
sensitivity analyses conducted. The Health Check was dominating
or cost-effective in all analyses and produced marginal cost
savings of £3.58 per person when no impact on early diagnosis
probability was assumed. In 100,000 probabilistic sensitivity
analysis iterations, use of the Health Check was found to be less
costly and more effective than the control on average. However,
due to the small differences in cost and effect, results are
distributed across all four sectors of the cost-effectiveness plane
(Supplementary Fig. 1). Overall, the probability that the Health
Check is cost-effective at willingness-to-pay thresholds of £20,000
and £30,000 per QALY gained is 88.6 and 95.5%, respectively
(Supplementary Fig. 2).
DISCUSSION
Summary of key findings
We conducted a randomised controlled trial to evaluate the
effectiveness of a novel targeted and tailored behaviour change
intervention designed to improve cancer awareness and address
barriers to symptom presentation among adults living in socio-
economically deprived communities of the UK. Differences in total
symptom recognition were not observed at short-term follow-up,
but there was evidence of longer-term knowledge retention and
shorter intended presentation among participants who received
the intervention. While baseline levels of symptom awareness
were high, recognition of “lesser known” symptoms such as
persistent fatigue and unexplained weight loss improved, and
there was no evidence of increased anxiety due to taking part in
the Health Check. Effects on perceived barriers to symptom
presentation and beliefs about cancer were not observed. The
Health Check intervention was delivered at low cost and did not
generate additional healthcare resource use in the six months
post intervention.
Discussion of findings within context of the literature
The design and evaluation of cancer awareness interventions is
challenging for several reasons. Intervention intensity and
duration are often limited by financial constraints, and evaluation
methods are typically restricted to observational designs with
short follow-up (e.g. Ironmonger et al. [18], McCutchan et al. [20]).
Furthermore, designing robust controlled trials of cancer aware-
ness interventions is problematic due to the demands of selecting
a suitable comparator and outcome measures, which may
inadvertently compromise intervention design and dose. The
Improving Rural Cancer Outcomes trial was unique in randomis-
ing whole communities in Western Australia to receive a symptom
awareness campaign in intervention areas compared to a
matched control area [37]. However, no significant intervention
effects were observed, possibly reflecting the omission of TV
broadcast media from the intervention due to concerns about
cost and trial contamination. Personalised behaviour change
interventions can aid in encouraging members of the public to
engage with health services, as reported in a trial that assessed
the effectiveness of a targeted GP postal letter to increase patient
consultation rates for possible cancer symptoms. While an
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intervention arm participants was observed in this trial, the total
number of patients with whom these took place did not increase
[38]. Further targeted public health interventions are needed to
engage those less likely to engage with cancer awareness
initiatives and address the persistent socioeconomic disparity in
cancer outcomes [39].
To our knowledge, the ABACus trial is the first to detail a
complex behavioural cancer awareness intervention that success-
fully reached and engaged a highly deprived target population
[27] and effected change in awareness and anticipated presenta-
tion for a range of common cancer symptoms. We used the
validated Awareness and Beliefs about Cancer measure [32],
adapted to low literacy levels and with additional measures of
barriers derived from the Cancer Awareness Measure [40]. The
finding of a baseline ceiling effect in participants’ recognition of
potential cancer symptoms is suggestive of measurement
reactivity [41–43] and may partly reflect the effect of completing
baseline measures immediately prior to intervention delivery. This
is similar to Hubbard et al. [44], who found subtle increases in
cancer awareness among adolescents enrolled in a trial of a brief
school-based cancer awareness intervention. Following participa-
tion in a cancer awareness roadshow, Smith et al. [45] reported
increased awareness of cancer risk factors and help-seeking
behaviour but not increased symptom knowledge, which they
attributed to ceiling effects and low intervention dose. However,
we found that symptom knowledge was retained six months post-
intervention, suggesting that more intensive individually
tailored and facilitated awareness interventions may be more
effective for the target population over a longer period. Never-
theless, the development of guidance to support the minimisation
of bias due to measurement reactions in studies of complex health
interventions [46] is welcome and will improve future evaluation
methods.
Strengths and limitations
A key strength is that the intervention was developed based on
the Medical Research Council guidelines for developing and
evaluating complex interventions [47] and principles of co-
production and was grounded in a theoretical understanding of
the behavioural influences on cancer awareness and help-seeking
in the target population [26, 48]. The trial was sufficiently powered
to detect changes in symptom awareness and the process
evaluation indicates that the ability to tailor the intervention to
individual needs and the personalised, facilitated nature of its
delivery most likely explain its positive impact on awareness and
anticipated presentation (HQ-S, YM, SG, SS, VS, JH, et al.
unpublished). However, it is unknown whether and to what
extent control arm participants were exposed to other local or
national cancer awareness campaigns and how these may have
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Fig. 2 Percentage of participant responses for “well know” and “lesser known” cancer symptoms. Percentage of responses in cancer
symptoms.
Table 3. Regression analyses for sub-scores generated by factor analysis.
Outcome measures Baseline 2 weeks follow-up Adjusted mean differencea
Control Health Check Control Health Check
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Difference (95% CI), p value
Cancer Symptom Recognition score (ABC) (7 items) 117 4.5 (2.17) 117 4.4 (2.13) 108 4.2 (2.37) 103 4.6 (2.20) 0.5 (0.03, 0.97), 0.04
Cancer Symptom Recognition score (ABC) (5 items) 117 4.5 (0.85) 117 4.5 (0.95) 109 4.4 (1.00) 103 4.4 (0.89) 0.1 (−0.16, 0.27), 0.61
Baseline 6 months follow-up
Control Health Check Control Health Check
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Cancer Symptom Recognition score (ABC) (7 items) 117 4.5 (2.17) 117 4.4 (2.13) 104 4.4 (2.17) 94 5.1 (2.15) 0.7 (0.16, 1.17), 0.01
Cancer Symptom Recognition score (ABC) (5 items) 117 4.5 (0.85) 117 4.5 (0.95) 104 4.5 (0.71) 95 4.6 (0.73) 0.1 (−0.09, 0.28), 0.31
aAdjusted for stratification (lay advisor) and baseline score.
Y. Moriarty et al.
7
British Journal of Cancer
We recognise the limitations of using self-report measures of
knowledge, beliefs and behaviour and of measuring anticipated
rather than actual symptom presentation behaviour, which may
help to explain lack of observed effects. We acknowledge the low
internal consistency of the adapted ABC cancer belief measure. The
ABC measure was adapted to account for low literacy levels within
our target population and we recognise that there is a need to
further develop and test psychometrically robust measures of
beliefs about cancer for use within this population group. Our
sample also consisted of predominantly white British and native
English speakers, further limiting the generalisability of the findings
to a wider UK population including mixed ethnic groups and non-
native English speakers who may present with additional needs
not addressed by our intervention. Future UK-wide implementa-
tion of the Health Check would need to consider any adaptations
required to accommodate the needs of these populations.
Implication for policy/practice and research
The intervention has the potential to achieve public health
benefits by encouraging cancer awareness and earlier presenta-
tion in socioeconomically deprived communities, with a lower cost
than the median observed for public health interventions
between 2011 and 2016 in the UK [49]. Our exploratory, model-
based cost-utility analysis showed that the Health Check has the
potential to be cost-effective, or even cost-saving, over the longer
term by potentially reducing later stage diagnosis and therefore
improving longer-term outcomes [50, 51]. Further prospective,
longer-term follow-up of larger cohorts using routine service data
would provide more confidence in the effects of the Health Check
on delays in symptom presentation, cancer stage at diagnosis and
cancer outcomes, all of which affect cost-effectiveness.
Non-specific symptoms [52] such as persistent fatigue and
unexplained weight loss are particularly difficult for people to
recognise and are more likely to be dismissed than classic “well-
known” symptoms such as lumps and unexplained bleeding,
because they can more easily be misattributed to the after effects
of major illnesses, natural everyday occurrences such as minor
illnesses, stress or the ageing process [9, 53, 54]. Individually
tailored and demographically targeted community-based cancer
awareness interventions such as the ABACus Health Check may
complement the recently implemented Multidisciplinary/Rapid
Diagnostic Centre referral pathways in England [55] and Wales [56]
by increasing public awareness and prompting action in response
to “lesser known”, common cancer symptoms that are predictive
of earlier stage disease [51]. Such initiatives may be important in
responding to the impact of the coronavirus disease 2019
pandemic on symptomatic presentation in primary care [57, 58].
Our model of trained peer supporters delivering cancer
awareness messages may present future implementation chal-
lenges within the UK health service provision system. However,
the findings of improved cancer symptom recognition over a
longer period, particularly for non-specific symptoms, are
encouraging. There is potential for this model to be embedded
and integrated across primary care, third-sector organisations and
Table 4. Mean per participant cost of healthcare resources (£) used in the 6 months post-randomisation (6-month follow-up measurements); all
available cases.
Healthcare resource Health Check group (n= 93) Control group (n= 103) Difference; 95% CI p value
Primary care costs
GP surgery visits (SD) 9.60 (39.83) 9.72 (27.81) −0.12; −9.72 to 9.49 0.981
Home visits (SD) 0.00 (0.00) 0.63 (6.34) −0.63; −1.92 to 0.67 0.343
Phone consultations (SD) 0.54 (3.17) 0.49 (3.01) 0.05; −0.82 to 0.92 0.905
NHS Direct phone call (SD) 0.00 (0.00) 0.00 (0.00) n/a n/a
Total cost of primary care use per
participant (SD)
10.14 (40.65) 10.84 (29.83) −0.69; −10.67 to 9.29 0.892
Secondary care costs
A&E visits (SD) 1.94 (18.75) 3.11 (22.41) −1.17; −7.02 to 4.69 0.695
Emergency admissions (SD) 22.22 (214.24) 5.01 (50.89) 17.20; −25.70 to 60.11 0.430
Ambulance call-outs (SD) 2.71 (26.12) 4.31 (43.75) −1.60; −11.89 to 8.69 0.759
Outpatient visits (SD) 19.32 (63.13) 30.87 (119.23) −11.55; −38.85 to 15.75 0.405
Elective inpatient stays (SD) 0.00 (0.00) 38.29 (388.60) −38.29; −117.78 to 41.20 0.343
Total secondary care cost per participant (SD) 46.19 (278.54) 81.60 (551.27) −35.40; −160.49 to 89.68 0.577
Investigation costs
Diagnostic imaging (SD) 13.23 (44.61) 13.19 (47.89) 0.04; −13.04 to 13.12 0.995
Blood tests (SD) 6.98 (35.71) 15.76 (90.76) −8.78; −28.60 to 11.04 0.383
Endoscopy (SD) 19.97 (78.12) 3.28 (23.41) 16.69; −0.01 to 33.39 0.050a
Biopsy (SD) 35.35 (224.03) 20.31 (86.39) 15.04; −31.94 to 62.01 0.529
Smear test (SD) 0.91 (8.78) 0.00 (0.00) 0.91; −0.90 to 2.72 0.320
Total investigation cost per participant (SD) 76.44 (350.79) 52.54 (188.19) 23.90; −54.37 to 102.17 0.548
Other costs
Cancer advice (SD) 1.71 (7.51) 1.15 (6.13) 0.56; −1.37 to 2.48 0.568
Total cost of potential cancer investigation (SD) 134.48 (641.41) 146.12 (682.48) −11.64; −198.77 to 175.50 0.903
Cancer treatment costs
Radiotherapy (SD) 0.00 (0.00) 5.64 (57.29) −5.64; −17.36 to 6.07 0.343
Chemotherapy (SD) 0.00 (0.00) 0.00 (0.00) n/a n/a
Surgery (SD) 0.00 (0.00) 146.03 (881.47) −146.03; −318.31 to 26.24 0.096
Total cancer treatment cost per participant (SD) 0.00 (0.00) 151.68 (920.43) −151.68; −331.57 to 28.21 0.098
CI confidence interval, n sample size, SD standard deviation, n/a not applicable.
aResult no longer statistically significant after Bonferroni–Holm correction for multiple comparisons.
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large employers and to be further adapted to investigate how this
approach can be used across diverse communities (i.e. ethnic
minorities, non-English speakers). However, this would require
significant adaptations to accommodate cultural sensitivities and
language barriers and further investigation to identify potential
obstacles for wide-scale implementation and normalisation within
a diverse UK context.
Summary
The ABACus Health Check is a viable low-cost intervention to
increase cancer awareness and encourage earlier symptom
presentation in socioeconomically deprived communities in the
UK. Further implementation research is needed to collect longer-
term presentation, diagnosis and outcome data and to evaluate
whether the intervention can be scaled up and rolled out in the
UK’s socioeconomically deprived communities.
DATA AVAILABILITY
De-identified participant data will be made available to the scientific community
upon request with an agreed/signed data sharing agreement.
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